Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan.
Low-molecular-weight heparins (LMWH) represent depolymerized porcine mucosal heparin derivatives, which are commonly used for the management of thrombotic disorders. Because of their widespread usage, the supplies of the raw material namely unfractionated heparin are nearly exhausted. Porcine mucosal tissue is almost exclusively used for the preparation of these agents. Thus, there is a timely need for the production of heparin like drugs from other sources. Fermentation techniques have been used to produce carbohydrates such as dextran and innulin for therapeutic purposes. Bacterial cell wall polysaccharide mimics the linear hexose units, which constitute heparin. Utilizing Escherichia coli cell membranes produced by fermentation technology, chemical sulfation and enzymatic epimerization, sulfaminoheparosan type of polymer mimicking the structure of heparin has been produced. These semi-synthetic sulfaminoheparosans exhibit biologic actions comparable to that observed with heparin. The sulfaminoheparosan core can also be degraded to obtain low-molecular-weight (LMW) derivatives mimicking LMWHs. Using this technique, a novel LMW sulfaminoheparosan derivative (Q93C/239) was produced by Inalco, Milan, Italy. To compare this heparin analogue, a LMWH, namely tinzaparin, was used to determine the relative anticoagulant, antiprotease, and molecular profile. Additional studies were carried out to determine the susceptibility of this agent to heparinase-I. These comparative studies exhibited both antiprotease and anticoagulant properties similar to those of tinzaparin. However LMW sulfaminoheparosan resisted heparinase-I digestion at low heparinase-I concentrations. These studies demonstrate that the sulfaminoheparosan derived LMW components exhibit similar molecular and anticoagulant profile as tinzaparin and warrant additional preclinical and clinical development to determine their potential usefulness as antithrombotic agents.
Loyola University Medical Center, Thrombosis and Hemostasis Research Laboratories, Maywood, IL 60153, USA.
Jyothi
J
Maddineni
Qing
Q
Ma
Debra A
DA
Hoppensteadt
Muzaffer
M
Demir
Marco
M
Manoni
Umberto
U
Cornelli
Jawed
J
Fareed
D000925:Anticoagulants / Q000737:chemistry / Q000494:pharmacology*; D001419:Bacteria / Q000737:chemistry; D001777:Blood Coagulation / Q000187:drug effects; D015951:Factor Xa / Q000096:biosynthesis; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000737:chemistry / Q000494:pharmacology*; D019763:Heparin Lyase / Q000378:metabolism; D006495:Heparin, Low-Molecular-Weight / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008970:Molecular Weight; D010314:Partial Thromboplastin Time; D011480:Protease Inhibitors; D011516:Prothrombin / Q000037:antagonists & inhibitors; D013917:Thrombin / Q000096:biosynthesis; D000078222:Tinzaparin
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D011480:Protease Inhibitors; C492930:Q93C-239 sulfaminoheparosan; D000078222:Tinzaparin; D011516:Prothrombin; C025337:Factor IIa; D006493:Heparin; D013917:Thrombin; D015951:Factor Xa; D019763:Heparin Lyase